Biogen (0R1B) Share Forecast & Price Target
0R1B Analyst Ratings
Moderate Buy
18Buy6Hold1Sell
Based on 25 analysts giving stock ratings to Biogen in the past 3 months
0R1B Stock 12 Month Forecast
Average Price Target
$263.20▲(4.25% Upside)Based on 25 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $263.20 with a high forecast of $325.00 and a low forecast of $175.00. The average price target represents a 4.25% change from the last price of $252.47.
Past 12 Months12 Month ForecastDec2025Sep2026
High$325.00
Average$263.20
Low$175.00
Highest Price TargetHighest$325.00Average Price Target$263.20Lowest Price TargetLowest$175.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jason Zemansky | Bank of America Securities | $257 | hold | 1.79%Upside | Reiterated | 10/29/26 | ||
| Geoff Meacham | Citi | $215→$255 | hold | 1.00%Upside | Reiterated | 10/29/26 | ||
| Phil Nadeau | TD Cowen | $250→$260 | buy | 2.98%Upside | Assigned | 10/29/26 | ||
| Mohit Bansal | Wells Fargo | $310 | buy | 22.79%Upside | Reiterated | 10/29/26 | ||
| Brian Skorney | Robert W. Baird | $250→$290 | buy | 14.87%Upside | Reiterated | 10/29/26 | ||
| Ami Fadia | Needham | $256→$290 | buy | 14.87%Upside | Reiterated | 10/29/26 | ||
| Sumant Kulkarni | Canaccord Genuity | $248→$272 | buy | 7.74%Upside | Reiterated | 10/29/26 | ||
| Evan Seigerman | BMO Capital | $220→$250 | hold | -0.98%Downside | Reiterated | 10/29/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | $260 | buy | 2.98%Upside | Reiterated | 10/29/26 | ||
| Laura Chico | Wedbush | $212→$225 | hold | -10.88%Downside | Reiterated | 10/29/26 | ||
| Michael Yee | UBS | $270→$300 | buy | 18.83%Upside | Assigned | 10/29/26 | ||
| Terence Flynn | Morgan Stanley | $238→$231 | hold | -8.50%Downside | Assigned | 10/29/26 | ||
| Jasper Hellweg | Argus Research | $280 | buy | 10.90%Upside | Upgraded | 10/29/26 | ||
| Ilya Zubkov | Freedom Capital Markets | $255→$275 | buy | 8.92%Upside | Reiterated | 10/29/26 | ||
| Paul Matteis | Stifel Nicolaus | $242→$286 | buy | 13.28%Upside | Reiterated | 10/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jason Zemansky | 10/29/26 | $257 | hold | 1.79%Upside | Reiterated | Bank of America Securities | ||
| Geoff Meacham | 10/29/26 | $215→$255 | hold | 1.00%Upside | Reiterated | Citi | ||
| Phil Nadeau | 10/29/26 | $250→$260 | buy | 2.98%Upside | Assigned | TD Cowen | ||
| Mohit Bansal | 10/29/26 | $310 | buy | 22.79%Upside | Reiterated | Wells Fargo | ||
| Brian Skorney | 10/29/26 | $250→$290 | buy | 14.87%Upside | Reiterated | Robert W. Baird | ||
| Ami Fadia | 10/29/26 | $256→$290 | buy | 14.87%Upside | Reiterated | Needham | ||
| Sumant Kulkarni | 10/29/26 | $248→$272 | buy | 7.74%Upside | Reiterated | Canaccord Genuity | ||
| Evan Seigerman | 10/29/26 | $220→$250 | hold | -0.98%Downside | Reiterated | BMO Capital | ||
| Unknown AnalystNot Ranked | 10/29/26 | $260 | buy | 2.98%Upside | Reiterated | Leerink Partners | ||
| Laura Chico | 10/29/26 | $212→$225 | hold | -10.88%Downside | Reiterated | Wedbush | ||
| Michael Yee | 10/29/26 | $270→$300 | buy | 18.83%Upside | Assigned | UBS | ||
| Terence Flynn | 10/29/26 | $238→$231 | hold | -8.50%Downside | Assigned | Morgan Stanley | ||
| Jasper Hellweg | 10/29/26 | $280 | buy | 10.90%Upside | Upgraded | Argus Research | ||
| Ilya Zubkov | 10/29/26 | $255→$275 | buy | 8.92%Upside | Reiterated | Freedom Capital Markets | ||
| Paul Matteis | 10/29/26 | $242→$286 | buy | 13.28%Upside | Reiterated | Stifel Nicolaus |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Biogen
3 Months
Success Rate16/27 ratings generated profit
59%
Average Return
+2.08%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +2.08% per trade.
1 Year
Success Rate16/23 ratings generated profit
70%
Average Return
+22.10%
Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +22.10% per trade.
2 Years
Success Rate15/23 ratings generated profit
65%
Average Return
+25.16%
Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +25.16% per trade.
0R1B Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 41 | 54 | 40 | 36 | 34 |
| Hold | 32 | 34 | 23 | 22 | 14 |
| Sell | 0 | 1 | 1 | 2 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 73 | 89 | 64 | 60 | 49 |
In the current month, 0R1B has received 34 Buy Ratings, 14 Hold Ratings, and 1 Sell Ratings. 0R1B average Analyst price target in the past 3 months is 263.20.
0R1B Financial Forecast
High$3.87
Consensus$2.86
Low$2.45
0R1B Earnings Forecast
Next quarter’s earnings estimate for 0R1B is $2.86 with a range of $2.45 to $3.87. The previous quarter’s EPS was $2.62. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$2.67B
Consensus$2.58B
Low$2.47B
0R1B Sales Forecast
Next quarter’s sales forecast for 0R1B is $2.58B with a range of $2.47B to $2.67B. The previous quarter’s sales results were $2.69B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0R1B Stock Forecast FAQ
What is GB:0R1B’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is $263.20.
What is GB:0R1B’s upside potential, based on the analysts’ average price target?
Biogen has 4.25% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Biogen a Buy, Sell or Hold?
Biogen has a consensus rating of Moderate Buy, which is based on 18 buy ratings, 6 hold ratings and 1 sell ratings.
What is Biogen’s share price target?
The average share price target for Biogen is $263.20. This is based on 25 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $325.00, and the lowest forecast is $175.00. The average share price target represents a 4.25% increase from the current price of $252.47.
What do analysts say about Biogen?
Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Street analysts.
How can I buy shares of Biogen?
To buy shares of GB:0R1B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.